Statera BioPharma (STU:7CB) Cash-to-Debt : 0.07 (As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Statera BioPharma Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Statera BioPharma's cash to debt ratio for the quarter that ended in Sep. 2022 was 0.07.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Statera BioPharma couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2022.

The historical rank and industry rank for Statera BioPharma's Cash-to-Debt or its related term are showing as below:

STU:7CB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.09 Max: 0.57
Current: 0.07

During the past 3 years, Statera BioPharma's highest Cash to Debt Ratio was 0.57. The lowest was 0.00. And the median was 0.09.

STU:7CB's Cash-to-Debt is not ranked
in the Biotechnology industry.
Industry Median: 6.89 vs STU:7CB: 0.07

Statera BioPharma Cash-to-Debt Historical Data

The historical data trend for Statera BioPharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Statera BioPharma Cash-to-Debt Chart

Statera BioPharma Annual Data

Trend

Dec19

Dec20

Dec21

Cash-to-Debt

0.30

0.12

Statera BioPharma Quarterly Data
	Dec19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Cash-to-Debt	Get a 7-Day Free Trial						0.57	0.12	0.05	0.10	0.07

Competitive Comparison of Statera BioPharma's Cash-to-Debt

For the Biotechnology subindustry, Statera BioPharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Statera BioPharma's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Statera BioPharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Statera BioPharma's Cash-to-Debt falls into.

Statera BioPharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Statera BioPharma's Cash to Debt Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.751	/	(4.275	+	10.116)
	=	0.12

Statera BioPharma's Cash to Debt Ratio for the quarter that ended in Sep. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.511	/	(6.787	+	0.693)
	=	0.07

Statera BioPharma (STU:7CB) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Statera BioPharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Statera BioPharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Statera BioPharma (STU:7CB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Statera BioPharma Inc (STU:7CB) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

4333 Corbett Drive, Suite 1082, Fort Collins, CO, USA, 80525

Website

https://www.staterabiopharma.com

Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction.

Statera BioPharma (STU:7CB) Headlines

No Headlines